$SUND
Sundance Strategies, Inc. Stock $sund

$sund Overview Financials Valuation SEC Filings Company Website

2015 Form 10-K Financial Statement

#000101041215000084 Filed on June 15, 2015

Income Statement

Concept	2015	2014 Q1	2014
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.338M	$920.0K	$2.280M
YoY Change	2.56%	1214.29%	2180.0%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	-$116.2K	$70.00K	$1.770M
YoY Change	-106.57%	-28.63%	1670.0%
Operating Profit	$116.2K		-$1.770M
YoY Change	-106.57%
Interest Expense	$287.2K	-$20.00K	$122.5K
YoY Change	134.54%	-404.09%	-1324.52%
% of Operating Profit	247.14%
Other Income/Expense, Net	-$263.0K	-$850.0K	$1.563M
YoY Change	-116.82%	12823.83%
Pretax Income	-$146.7K	-$90.00K	-$206.1K
YoY Change	-28.81%	-14.0%	106.14%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$146.7K	-$90.00K	-$206.1K
YoY Change	-28.81%	-14.0%	106.14%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$3.402K	-$1.966K	-$4.934K
COMMON SHARES
Basic Shares Outstanding		42.92M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015	2014 Q1	2014
SHORT-TERM ASSETS
Cash & Short-Term Investments	$336.4K	$380.0K	$380.0K
YoY Change	-11.48%	-30.91%	-30.91%
Cash & Equivalents	$336.4K	$375.2K	$380.0K
Short-Term Investments
Other Short-Term Assets	$1.880K	$0.00	$0.00
YoY Change
Inventory
Prepaid Expenses		$2.000K
Receivables
Other Receivables
Total Short-Term Assets	$338.3K	$377.2K	$380.0K
YoY Change	-10.99%	-30.84%	-30.91%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$26.14M	$15.83M	$15.83M
YoY Change	65.14%	151.27%	151.27%
Other Assets	$16.43K	$3.585M	$10.00K
YoY Change	64.3%
Total Long-Term Assets	$26.37M	$16.70M	$16.70M
YoY Change	57.89%	165.17%	165.5%
TOTAL ASSETS
Total Short-Term Assets	$338.3K	$377.2K	$380.0K
Total Long-Term Assets	$26.37M	$16.70M	$16.70M
Total Assets	$26.71M	$17.08M	$17.08M
YoY Change	56.36%	149.55%	149.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$255.4K	$52.92K	$50.00K
YoY Change	410.72%	-40.6%	-44.44%
Accrued Expenses	$181.9K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$1.327M	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due	$1.500M	$90.00K	$90.00K
YoY Change	1566.67%
Total Short-Term Liabilities	$3.264M	$142.9K	$140.0K
YoY Change	2231.54%	-95.38%	-95.48%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$1.460M	$1.460M
YoY Change	-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$1.460M	$1.460M
YoY Change	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.264M	$142.9K	$140.0K
Total Long-Term Liabilities	$0.00	$1.460M	$1.460M
Total Liabilities	$3.264M	$1.599M	$1.600M
YoY Change	104.01%	-48.35%	-48.39%
SHAREHOLDERS EQUITY
Retained Earnings		-$310.8K
YoY Change		196.98%
Common Stock		$15.09M
YoY Change		36896.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$23.44M	$15.48M	$15.48M
YoY Change
Total Liabilities & Shareholders Equity	$26.71M	$17.08M	$17.08M
YoY Change	56.36%	149.55%	149.71%

Cashflow Statement

Concept	2015	2014 Q1	2014
OPERATING ACTIVITIES
Net Income	-$146.7K	-$90.00K	-$206.1K
YoY Change	-28.81%	-14.0%	106.14%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$1.999M	-$870.0K	-$10.47M
YoY Change	-80.91%	-73.82%	215.36%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$400.0K	$0.00	-$860.0K
YoY Change	-146.51%
Cash From Investing Activities	$400.0K	$0.00	-$860.0K
YoY Change	-146.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$150.0K		$10.46M
YoY Change	-98.57%		170.33%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.560M	1.120M	11.16M
YoY Change	-86.02%	-71.05%	188.37%
NET CHANGE
Cash From Operating Activities	-1.999M	-870.0K	-10.47M
Cash From Investing Activities	400.0K	0.000	-860.0K
Cash From Financing Activities	1.560M	1.120M	11.16M
Net Change In Cash	-38.84K	250.0K	-170.0K
YoY Change	-77.15%	-54.16%	-130.91%
FREE CASH FLOW
Cash From Operating Activities	-$1.999M	-$870.0K	-$10.47M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable		USD
CY2014Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	1455904	USD
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2015Q1	us-gaap	Liabilities Liabilities	3264154	USD
CY2014Q1	us-gaap	Liabilities Liabilities	1598819	USD
CY2015Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q1	sund	Additional Paid In Capital Stock To Be Issued AdditionalPaidInCapitalStockToBeIssued	700000	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-310789	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	15481433	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	43186	USD
CY2015Q1	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock		USD
CY2014Q1	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	1500	USD
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	15050705	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26706694	USD
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43185941	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43015941	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43185941	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015	us-gaap	Interest Income Operating InterestIncomeOperating	2454478	USD
CY2014	us-gaap	Interest Income Operating InterestIncomeOperating	508411	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2338265	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2278009	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	116213	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-1769598	USD
CY2015	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		USD
CY2014	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1672124	USD
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	17947	USD
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	13788	USD
CY2015	us-gaap	Interest Expense InterestExpense	287203	USD
CY2014	us-gaap	Interest Expense InterestExpense	122452	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6303	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-262953	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1563460	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-146740	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-206138	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-146740	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-206138	USD
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42559660	shares
CY2015	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	417846	USD
CY2014	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	816802	USD
CY2015	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	815798	USD
CY2014	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	3584862	USD
CY2015	sund	Refund Of Advance For Investments In Net Insurance Benefits RefundOfAdvanceForInvestmentsInNetInsuranceBenefits	904274	USD
CY2015	sund	Distribution Of Life Settlement Contract Investments DistributionOfLifeSettlementContractInvestments		USD
CY2014	sund	Refund Of Advance For Investments In Net Insurance Benefits RefundOfAdvanceForInvestmentsInNetInsuranceBenefits		USD
CY2015	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	9405	USD
CY2014	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	13767	USD
CY2015	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-125	USD
CY2014	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	202446	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	135420	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	52888	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities		USD
CY2015	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2604478	USD
CY2014	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	5944411	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1998842	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10471080	USD
CY2015	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	150000	USD
CY2014	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	861000	USD
CY2015	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	-550000	USD
CY2014	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable		USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	400000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-861000	USD
CY2015	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	1410000	USD
CY2014	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	150000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10461875	USD
CY2015	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity		USD
CY2014	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	700000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1560000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	11161875	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-38842	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-170205	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	545417	USD
CY2015	us-gaap	Interest Paid InterestPaid	117471	USD
CY2014	us-gaap	Interest Paid InterestPaid		USD
CY2015	us-gaap	Notes Reduction NotesReduction	100000	USD
CY2014	us-gaap	Notes Reduction NotesReduction		USD
CY2015	sund	Fair Value Of Warrants Issued Stock Issuance Costs FairValueOfWarrantsIssuedStockIssuanceCosts		USD
CY2014	sund	Fair Value Of Warrants Issued Stock Issuance Costs FairValueOfWarrantsIssuedStockIssuanceCosts	139251	USD
CY2015	us-gaap	Stock Issued1 StockIssued1	7540000	USD
CY2014	us-gaap	Stock Issued1 StockIssued1		USD
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Registrant Name EntityRegistrantName	Sundance Strategies, Inc.
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0001171838
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44222191	shares
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2014	sund	Distribution Of Life Settlement Contract Investments DistributionOfLifeSettlementContractInvestments		USD
CY2015	us-gaap	Impairment Of Investments ImpairmentOfInvestments		USD
CY2014	us-gaap	Impairment Of Investments ImpairmentOfInvestments		USD
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: 'times new roman';"><font style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Estimates,</font><font style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;">The preparation of financial statements in conformity with</font><font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;">accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.</font></p> </div>
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInNextTwelveMonths		item
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodFaceValueMaturingInNextTwelveMonths		USD
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Two LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearTwo	1	item
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Two LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearTwo	10000000	USD
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing After Year Five LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingAfterYearFive	49	item
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Three LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearThree	4	item
CY2015	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><p style="margin: 0pt; font-family: 'times new roman';"><font style="font-family: 'Times New Roman'; font-size: 10pt;"><strong>(3) NEW ACCOUNTING PRONOUNCEMENTS</strong></font></p> <p style="margin: 0pt; font-family: 'times new roman';"><font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font></p> <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: 'times new roman';"><font style="font-family: 'Times New Roman'; font-size: 10pt;">In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2014-09 Revenue from Contracts with Customers, which provides a single, comprehensive revenue recognition model for all contracts with customers. The core principal of this ASU is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This ASU is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2016. Early adoption is not permitted and companies can transition to the new standard under the full retrospective method or the modified retrospective method. The Company does not believe adoption of this ASU will have a material impact on its financial statements.</font></p> <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: 'times new roman';"><font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font></p> <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: 'times new roman';"><font style="font-family: 'Times New Roman'; font-size: 10pt;">In August 2014, the FASB issued ASU 2014-15 Presentation of Financial StatementsGoing Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. The new standard provides guidance around management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company's financial statements.</font></p> <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: 'times new roman';"><font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font></p> <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: 'times new roman';"><font style="font-family: 'Times New Roman'; font-size: 10pt;">In April, 2015, the FASB issued ASU 2015-03,</font><font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;">Simplifying the Presentation of Debt Issuance Costs (Subtopic 835-30)</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;">This update requires debt issuance costs to be presented in the balance sheet as a direct deduction from the associated debt liability. Under current standards, debt issuance costs are generally recorded as an asset and amortization of these deferred financing costs is recorded in interest expense.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;">Under the new standard, debt issuance costs will continue to be amortized over the life of the debt instrument and amortization will continue to be recorded in interest expense.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;">ASU 2015-03 is effe</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">ctive for the Company on January 1</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">, 2016, and will be applied on a retrospective basis.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;">The Company is currently evaluating the impact this guidance will have on our consolidated financial statements</font><font style="font-family: 'Times New Roman'; font-size: 10pt;">.</font><font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font></p> <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: 'times new roman';"><font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font></p> <p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: 'times new roman';"><font style="font-family: 'Times New Roman'; font-size: 10pt;">The Company has reviewed all other recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.</font></p></div>
CY2015Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Three LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearThree	16975000	USD
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Four LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearFour	4	item
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Four LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearFour	25500000	USD
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Five LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearFive	3	item
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Five LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearFive	14500000	USD
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing After Year Five LifeSettlementContractsInvestmentMethodFaceValueMaturingAfterYearFive	274221882	USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Three LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearThree	19049536	USD
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Four LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearFour	12549610	USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Four LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearFour	7426329	USD
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts LifeSettlementContractsInvestmentMethodNumberOfContracts	61	item
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	341196882	USD
CY2013Q1	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	6299000	USD
CY2015	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	7846746	USD
CY2014	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	5436000	USD
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Next Twelve Months LifeSettlementContractsInvestmentMethodPremiumsToBePaidInNextTwelveMonths	11737717	USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Expenses Plus Interest In Next Twelve Months LifeSettlementContractsInvestmentMethodExpensesPlusInterestInNextTwelveMonths	8882609	USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Next Twelve Months LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInNextTwelveMonths	20620326	USD
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Two LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearTwo	11167772	USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Two LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearTwo	7451554	USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Two LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearTwo	18619326	USD
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Three LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearThree	10994514	USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Three LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearThree	8055022	USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Four LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearFour	19975939	USD
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Five LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearFive	11777714	USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Five LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearFive	6135891	USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Five LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearFive	17913605	USD
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Five Year Disclosure Premiums To Be Paid LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid	104241637	USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid Total LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidTotal	68714231	USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaid	172955868	USD
CY2015	sund	Life Settlement Contracts Matured During Period LifeSettlementContractsMaturedDuringPeriod	8000000	USD
CY2015	sund	Life Settlement Contracts Investment Method Premiums Paid And Other Expenses LifeSettlementContractsInvestmentMethodPremiumsPaidAndOtherExpenses	71855560	USD
CY2015Q1	sund	Face Value Of Net Insurance Benefits Purchased Under Asset Transfer Agreement FaceValueOfNetInsuranceBenefitsPurchasedUnderAssetTransferAgreement	400000000	USD
CY2015	sund	Value Of Qualified Net Insurance Benefits ValueOfQualifiedNetInsuranceBenefits	90600000	USD
CY2015	us-gaap	Restructuring And Related Cost Incurred Cost RestructuringAndRelatedCostIncurredCost	4000000	USD
CY2015Q1	sund	Total Cash Consideration That Would Be Paid By Company If All Net Insurance Benefits Are Provided Under Asset Transfer Agreement TotalCashConsiderationThatWouldBePaidByCompanyIfAllNetInsuranceBenefitsAreProvidedUnderAssetTransferAgreement	8000000	USD
CY2015	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	24000000	USD
CY2015Q1	sund	Total Notes Payable That Would Be Issued By Company If All Net Insurance Benefits Are Provided Under Asset Transfer Agreement TotalNotesPayableThatWouldBeIssuedByCompanyIfAllNetInsuranceBenefitsAreProvidedUnderAssetTransferAgreement	12000000	USD
CY2015	us-gaap	Debt Instrument Term DebtInstrumentTerm	P2Y
CY2015Q1	sund	Value Of Net Insurance Benefits Required To Be Delivered Per Asset Transfer Agreement ValueOfNetInsuranceBenefitsRequiredToBeDeliveredPerAssetTransferAgreement	300000000	USD
CY2015	sund	Advance To Consultant For Services AdvanceToConsultantForServices	25000	USD
CY2013Q2	sund	Maximum Number Of Common Shares Offered Through Private Placement MaximumNumberOfCommonSharesOfferedThroughPrivatePlacement	3000000	shares
CY2013Q2	us-gaap	Share Price SharePrice	5.00
CY2014	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	11792500	USD
CY2014	us-gaap	Stock Issued During Period Shares Period Increase Decrease StockIssuedDuringPeriodSharesPeriodIncreaseDecrease	2358500	shares
CY2014	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2218500	shares
CY2014Q1	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	140000	shares
CY2014Q1	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	700000	USD
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	841651	USD
CY2014	sund	Warrant Term WarrantTerm	P2Y
CY2014Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	70000	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.00
CY2014Q4	us-gaap	Notes And Loans Receivable Gross Current NotesAndLoansReceivableGrossCurrent	150000	USD
CY2014Q2	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	74255	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	91529	USD
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		USD
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		USD
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		USD
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		USD
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	676558	USD
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	485850	USD
CY2015	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-742224	USD
CY2014	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-533006	USD
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	65666	USD
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-47156	USD
CY2015Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		USD
CY2014Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		USD
CY2015	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments		USD
CY2015Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1574512	USD
CY2014Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	760250	USD
CY2015Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	512465	USD
CY2014Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	356608	USD
CY2015Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	358117	USD
CY2014Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	303518	USD
CY2015Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1728860	USD
CY2014Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	813340	USD
CY2015Q1	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	1728860	USD
CY2014Q1	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	813340	USD
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-49892	USD
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-70087	USD
CY2015	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-4842	USD
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-6803	USD
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	135	USD
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	2395	USD
CY2014	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-188209	USD
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	54599	USD
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	262704	USD
CY2015Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	4221212	USD
CY2014Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2038201	USD
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	417846	USD
CY2015Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	691084	USD
CY2015	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y1M2D
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2013Q1	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.00
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2185000	shares
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.54
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.85
CY2014	sund	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2	P4Y6M
CY2014	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue	3374450	USD
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2014	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue
CY2014	sund	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm2
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2014	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresWeightedAverageGrantDateFairValue
CY2014	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue		USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2185000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.54
CY2014Q1	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	1.85
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y6M
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3374450	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1072500	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	1.54
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.85
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y6M
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1656338	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2015	sund	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2
CY2015	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue		USD
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2015	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue
CY2015	sund	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm2
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2015	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresWeightedAverageGrantDateFairValue
CY2015	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue		USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2185000	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.54
CY2015Q1	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	1.85
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y6M
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3374450	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1506875	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	1.54
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.85
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y6M
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	2327174	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2185000	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.54
CY2015Q1	sund	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue	1.85
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y6M
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	3374450	USD
CY2013Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	70000	shares
CY2015Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	70000	shares
CY2015Q1	us-gaap	Share Price SharePrice	5.00
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber		shares
CY2013Q1	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedOutstandingWeightedAverageExercisePrice
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	70000	shares
CY2014	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Intrinsic Value Extended ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValueExtended		USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2014	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercise Price Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceForfeitures
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2014	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageRemainingContractualTerms
CY2014	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled Or Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledOrExpiredInPeriodIntrinsicValue		USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	70000	shares
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	70000	shares
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested		USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod		shares
CY2015	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercise Price Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceGranted
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2015	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms
CY2015	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Intrinsic Value Extended ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValueExtended		USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2015	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercise Price Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceForfeitures
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2015	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageRemainingContractualTerms
CY2015	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled Or Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledOrExpiredInPeriodIntrinsicValue		USD
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		USD
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested		USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.92
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P1Y2M1D
CY2014	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice	5.00
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.92
CY2014	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms	P1Y2M1D
CY2014Q1	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedOutstandingWeightedAverageExercisePrice	5.00
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	70000	shares
CY2015Q1	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedOutstandingWeightedAverageExercisePrice	5.00
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.92
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2M1D
CY2014	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercise Price Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceGranted	5.00
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.92
CY2014	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms	P1Y2M1D
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	70000	shares
CY2015	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice	5.00
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.92
CY2015	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms	P2M1D
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	3748895	USD
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11092499	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	841651	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	700000	USD
CY2014	sund	Stockholders Equity Subscriptions Reveivable Increase StockholdersEquitySubscriptionsReveivableIncrease	31775	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	816802	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	139251	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	150000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	417847	USD
CY2015	sund	Adjustments To Additional Paid In Capital Removal Of Expired Subscription AdjustmentsToAdditionalPaidInCapitalRemovalOfExpiredSubscription		USD
CY2015	sund	Adjustments To Additional Paid In Capital Common Stock To Be Issued For Net Insurance Benefits AdjustmentsToAdditionalPaidInCapitalCommonStockToBeIssuedForNetInsuranceBenefits	7540000	USD
CY2015	sund	Stock Issued During Period Value Issuance Of Stock To Be Issued StockIssuedDuringPeriodValueIssuanceOfStockToBeIssued		USD
CY2014Q3	dei	Entity Public Float EntityPublicFloat	89225317	USD
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1766374	shares
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Premiums To Be Paid In Next Twelve Months LifeSettlementContractsHeldAsCollateralInvestmentMethodPremiumsToBePaidInNextTwelveMonths	2555383	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Expenses Plus Interest In Next Twelve Months LifeSettlementContractsHeldAsCollateralInvestmentMethodExpensesPlusInterestInNextTwelveMonths	1072007	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Next Twelve Months LifeSettlementContractsHeldAsCollateralInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInNextTwelveMonths	3627390	USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Number Of Contracts Held As Collateral Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodNumberOfContractsHeldAsCollateralMaturingInNextTwelveMonths		item
CY2015Q1	sund	Life Settlement Contracts Investment Method Number Of Contracts Held As Collateral Maturing In Year Two LifeSettlementContractsInvestmentMethodNumberOfContractsHeldAsCollateralMaturingInYearTwo		item
CY2015Q1	sund	Life Settlement Contracts Investment Method Number Of Contracts Held As Collateral Maturing In Year Three LifeSettlementContractsInvestmentMethodNumberOfContractsHeldAsCollateralMaturingInYearThree	2	item
CY2015Q1	sund	Life Settlement Contracts Investment Method Number Of Contracts Held As Collateral Maturing In Year Four LifeSettlementContractsInvestmentMethodNumberOfContractsHeldAsCollateralMaturingInYearFour		item
CY2015Q1	sund	Life Settlement Contracts Investment Method Number Of Contracts Held As Collateral Maturing In Year Five LifeSettlementContractsInvestmentMethodNumberOfContractsHeldAsCollateralMaturingInYearFive		item
CY2015Q1	sund	Life Settlement Contracts Investment Method Number Of Contracts Held As Collateral Maturing After Year Five LifeSettlementContractsInvestmentMethodNumberOfContractsHeldAsCollateralMaturingAfterYearFive	10	item
CY2015Q1	sund	Life Settlement Contracts Investment Method Number Of Contracts Held As Collateral LifeSettlementContractsInvestmentMethodNumberOfContractsHeldAsCollateral	12	item
CY2015Q1	sund	Life Settlement Contracts Investment Method Face Value Held As Collateral Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodFaceValueHeldAsCollateralMaturingInNextTwelveMonths		USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Face Value Held As Collateral Maturing In Year Two LifeSettlementContractsInvestmentMethodFaceValueHeldAsCollateralMaturingInYearTwo		USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Face Value Held As Collateral Maturing In Year Three LifeSettlementContractsInvestmentMethodFaceValueHeldAsCollateralMaturingInYearThree	15000000	USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Face Value Held As Collateral Maturing In Year Four LifeSettlementContractsInvestmentMethodFaceValueHeldAsCollateralMaturingInYearFour		USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Face Value Held As Collateral Maturing In Year Five LifeSettlementContractsInvestmentMethodFaceValueHeldAsCollateralMaturingInYearFive		USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Face Value Held As Collateral Maturing After Year Five LifeSettlementContractsInvestmentMethodFaceValueHeldAsCollateralMaturingAfterYearFive	79000000	USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Face Value Held As Collateral LifeSettlementContractsInvestmentMethodFaceValueHeldAsCollateral	94000000	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Premiums To Be Paid In Year Two LifeSettlementContractsHeldAsCollateralInvestmentMethodPremiumsToBePaidInYearTwo	2749390	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Expenses Plus Interest To Be Paid In Year Two LifeSettlementContractsHeldAsCollateralInvestmentMethodExpensesPlusInterestToBePaidInYearTwo	1452308	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Two LifeSettlementContractsHeldAsCollateralInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearTwo	4201698	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Premiums To Be Paid In Year Three LifeSettlementContractsHeldAsCollateralInvestmentMethodPremiumsToBePaidInYearThree	2859707	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Expenses Plus Interest To Be Paid In Year Three LifeSettlementContractsHeldAsCollateralInvestmentMethodExpensesPlusInterestToBePaidInYearThree	1197036	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Three LifeSettlementContractsHeldAsCollateralInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearThree	4056743	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Premiums To Be Paid In Year Four LifeSettlementContractsHeldAsCollateralInvestmentMethodPremiumsToBePaidInYearFour	2939673	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Expenses Plus Interest To Be Paid In Year Four LifeSettlementContractsHeldAsCollateralInvestmentMethodExpensesPlusInterestToBePaidInYearFour	1241008	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Four LifeSettlementContractsHeldAsCollateralInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearFour	4180681	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Premiums To Be Paid In Year Five LifeSettlementContractsHeldAsCollateralInvestmentMethodPremiumsToBePaidInYearFive	2772138	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Expenses Plus Interest To Be Paid In Year Five LifeSettlementContractsHeldAsCollateralInvestmentMethodExpensesPlusInterestToBePaidInYearFive	1199873	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Five LifeSettlementContractsHeldAsCollateralInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearFive	3972011	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Five Year Disclosure Premiums To Be Paid LifeSettlementContractsHeldAsCollateralInvestmentMethodFiveYearDisclosurePremiumsToBePaid	19331188	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Expenses Plus Interest To Be Paid Total LifeSettlementContractsHeldAsCollateralInvestmentMethodExpensesPlusInterestToBePaidTotal	14757547	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Premiums Plus Expenses Plus Interest To Be Paid LifeSettlementContractsHeldAsCollateralInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaid	34088735	USD
CY2014Q4	sund	Refund Of Advance For Investments In Net Insurance Benefits RefundOfAdvanceForInvestmentsInNetInsuranceBenefits	904274	USD
CY2015Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	187500	shares
CY2015Q1	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	8
CY2015Q1	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid After Year Five LifeSettlementContractsInvestmentMethodPremiumsToBePaidAfterYearFive	46014310	USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid After Year Five LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidAfterYearFive	30762826	USD
CY2014Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1110000	USD
CY2014Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	1362000	USD
CY2015Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	138000	USD
CY2015	us-gaap	Related Party Transaction Rate RelatedPartyTransactionRate	0.075	pure
CY2015	us-gaap	Loan Processing Fee LoanProcessingFee	180000	USD
CY2015Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	37350	USD
CY2015	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2015-04-01
CY2015	us-gaap	Debt Instrument Convertible Number Of Equity Instruments DebtInstrumentConvertibleNumberOfEquityInstruments	187500	item
CY2014Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	30000	shares
CY2014Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	150000	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1130000	shares
CY2015Q1	us-gaap	Notes Payable NotesPayable	1493254	USD
CY2015Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9040000	USD
CY2015Q1	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid After Year Five LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidAfterYearFive	76777136	USD
CY2015Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	7546746	USD
CY2014Q1	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	349196882	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Premiums To Be Paid After Year Five LifeSettlementContractsHeldAsCollateralInvestmentMethodPremiumsToBePaidAfterYearFive	5454897	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Expenses Plus Interest To Be Paid After Year Five LifeSettlementContractsHeldAsCollateralInvestmentMethodExpensesPlusInterestToBePaidAfterYearFive	8595315	USD
CY2015Q1	sund	Life Settlement Contracts Held As Collateral Investment Method Premiums Plus Expenses Plus Interest To Be Paid After Year Five LifeSettlementContractsHeldAsCollateralInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidAfterYearFive	14050212	USD
CY2015Q1	sund	Total Consideration That Would Be Paid By Company If All Net Insurance Benefits Are Provided Under Asset Transfer Agreement TotalConsiderationThatWouldBePaidByCompanyIfAllNetInsuranceBenefitsAreProvidedUnderAssetTransferAgreement	20000000	USD
CY2015Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.040	pure
CY2015Q1	us-gaap	Other Notes Payable OtherNotesPayable	12000000	USD
CY2015	us-gaap	Operating Loss Carryforwards Expiration Date OperatingLossCarryforwardsExpirationDate	2021-12-31
CY2015Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued		USD
CY2014Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued		USD
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense		USD
CY2015	sund	Liquidity And Capital Requirements Disclosure Textblock LiquidityAndCapitalRequirementsDisclosureTextblock	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="margin: 0in 0in 0pt; text-align: justify; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><b>(15)<font style="mso-spacerun: yes;">  </font>LIQUIDITY AND CAPITAL REQUIREMENTS</b></font></p> <p style="margin: 0in 0in 0pt; text-align: justify; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'times new roman', times; font-size: 10pt;"><b> </b></font></p> <p style="margin: 0in 0in 0pt; text-align: justify; text-indent: 0.5in; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">Under the current business plan, the Company purchases life insurance policies and residual interests in or financial products tied to life insurance policies when they fit its model and its cash flows are sufficient to fund those purchases (with exception of the Del Mar ATA wherein the Company committed to purchase a certain number of Qualified NIBs as Del Mar made them available (see Note 16 below for a description of events subsequent to year end relating to the Del Mar ATA). <font style="mso-spacerun: yes;"> </font>The Company expects to finance NIB purchases, as well as its operating working capital requirements, with proceeds from planned public and/or private offerings of its securities and debt financing. There can be no assurance that the Company will be successful in the anticipated equity and debt offerings or that it will be successful in raising additional capital in the future on terms acceptable to the Company, or at all.</font></p> <p style="margin: 0in 0in 0pt; text-align: justify; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;"> </font></p> <p style="margin: 0in 0in 0pt; text-align: justify; text-indent: 0.5in; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;">If the Company is unable to raise sufficient capital through the planned securities and debt offerings or other alternative sources of financing, management will curtail NIB purchases. Under this plan, expenditures for NIBs will be curtailed. The Company believes that it will be able to fund its operating working capital requirements with existing line-of-credit and debentures agreements.</font></p> <p style="margin: 0in 0in 0pt; text-align: justify; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'times new roman', times;"> </font></p> <p style="margin: 0in 0in 0pt; text-align: justify; text-indent: 0.5in; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-size: 10pt;">The accompanying financial statements have been prepared on a going concern basis under which the Company is expected to be able to realize its assets and satisfy its liabilities in the normal course of business. To continue as a going concern beyond the year ended March 31, 2016, and in order to continue to purchase NIBs, the Company will need to complete planned securities and debt offerings or obtain alternative sources of financing. Absent additional financing, the Company will not have the resources to execute its current business plan.</font></p> </div>

Files In Submission

Name	View Source	Status
0001010412-15-000084-index-headers.html	Edgar Link	pending
0001010412-15-000084-index.html	Edgar Link	pending
0001010412-15-000084.txt	Edgar Link	pending
0001010412-15-000084-xbrl.zip	Edgar Link	pending
amendmentno1toapahyperion.htm	Edgar Link	pending
ex311.htm	Edgar Link	pending
ex312.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hfiiassettransferagreementv8.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sund-20150331.xml	Edgar Link	completed
sund-20150331.xsd	Edgar Link	pending
sund-20150331_cal.xml	Edgar Link	unprocessable
sund-20150331_def.xml	Edgar Link	unprocessable
sund-20150331_lab.xml	Edgar Link	unprocessable
sund-20150331_pre.xml	Edgar Link	unprocessable
sundancestrategies10kannu001.jpg	Edgar Link	pending
sundancestrategies10kannualr.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SUND
Sundance Strategies, Inc. Stock $sund

2015 Form 10-K Financial Statement

#000101041215000084 Filed on June 15, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SUND Sundance Strategies, Inc. Stock $sund

2015 Form 10-K Financial Statement

#000101041215000084 Filed on June 15, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SUND
Sundance Strategies, Inc. Stock $sund